Masui Takuya, Hashimoto Ryota, Kusumi Ichiro, Suzuki Katsuji, Tanaka Teruaki, Nakagawa Shin, Suzuki Tatsuyo, Iwata Nakao, Ozaki Norio, Kato Tadafumi, Takeda Masatoshi, Kunugi Hiroshi, Koyama Tsukasa
Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):204-8. doi: 10.1016/j.pnpbp.2007.08.010. Epub 2007 Aug 19.
Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.
锂是治疗双相情感障碍最常用的药物之一。为了给患者合理开具锂剂处方，人们探索了该药物反应的预测指标，几种基因标记物被认为是很好的候选指标。我们之前报道了断裂簇区域（BCR）基因的遗传变异与双相情感障碍之间存在显著关联。在本研究中，我们检测了锂维持治疗反应与BCR基因中Asn796Ser单核苷酸多态性之间的可能关系。对161例服用锂剂至少1年的双相情感障碍患者进行基因分型，并将他们分为锂单药治疗反应者和无反应者。我们发现，无反应者中Ser796的等位基因频率显著高于反应者。有必要进行进一步研究以证实我们的发现。
